Industries > Pharma > Active Pharmaceutical Ingredients Market Report to 2031

Back to Pharma Reports

Active Pharmaceutical Ingredients Market Report to 2031

Forecasts by API (Branded/ Innovative and Generic), by Type of Synthesis (Synthetic and Biotech), by Application (Diabetes, Oncology, Cardiovascular, CNS, Analgesics, and Others) PLUS COVID-19 Recovery Scenarios

PAGES: 324

PRODUCT CODE: PHA1085

SUBMARKET: Therapeutic Drugs

DOWNLOAD FREE SAMPLE

SKU: PHA1085 Categories: Pharma, Therapeutic Drugs Tag: PHA1085

Active Pharmaceutical Ingredients Market – our new study reveals trends, R&D progress, and predicted revenues
Where the Active Pharmaceutical Ingredients is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities, and business prospects there.

Discover how to stay ahead
500+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and future market prospects. Our new study lets you assess forecasted sales at the overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Active Pharmaceutical Ingredients Market. See how to exploit opportunities.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles, and commercial developments.

Discover sales predictions for the world market and submarkets

Active Pharmaceutical Ingredients Market: By API
• Branded/ Innovative
• Generic

Active Pharmaceutical Ingredients Market: By Type of Synthesis
• Synthetic
• Biotech

Active Pharmaceutical Ingredients Market: Add Segmentation Here
• Diabetes
• Oncology
• Cardiovascular
• CNS
• Analgesics
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa

The report also includes profiles and for some of the leading companies in the Active Pharmaceutical Ingredients Market, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
Overall world revenue for Active Pharmaceutical Ingredients Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Active Pharmaceutical Ingredients Market report helps you
In summary, our 500+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Active Pharmaceutical Ingredients Market, with forecasts for API, Type of Synthesis, and Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Active Pharmaceutical Ingredients market in North America, Europe, Asia-Pacific, and Rest of the World. Also forecasted are the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Active Pharmaceutical Ingredients Market. Some of the companies profiled in this report include AbbVie Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N.V.; Cipla Inc.; Boehringer Ingelheim International GmbH; Merck & Co., Inc.; Sun Pharmaceutical Industries Ltd.; Bristol-Myers Squibb Company; Albemarle Corporation; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Active Pharmaceutical Ingredients Market Report to 2031: Forecasts by API (Branded/ Innovative and Generic), by Type of Synthesis (Synthetic and Biotech), by Application (Diabetes, Oncology, Cardiovascular, CNS, Analgesics, and Others) PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Active Pharmaceutical Ingredients Market
2.1. Active Pharmaceutical Ingredients Market Definition
2.2. API Submarkets Definitions
2.3. Type of Synthesis Submarkets Definitions
2.4. Application Submarkets Definitions
3. Active Pharmaceutical Ingredients Market Overview
3.1. Global Active Pharmaceutical Ingredients Market Size and Forecast by Region
3.2. Global Active Pharmaceutical Ingredients Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing incidence of chronic diseases
3.3.1.2. Technological advancements in API manufacturing
3.3.1.3. Growing importance of generics
3.3.1.4. Increasing uptake of biopharmaceuticals
3.3.1.5. Growing adoption of AI-based tools for drug discovery
3.3.1.6. Adoption of organ-on-chip models in drug development
3.3.1.7. Focus on precision medicine
3.3.1.8. Investments in real-world evidence by pharmaceutical companies
3.3.2. Market Restraints/Challenges
3.3.2.1. Unfavorable drug price control policies
3.3.2.2. High manufacturing costs
3.3.2.3. Increasing penetration of counterfeit drugs
3.3.3. Opportunities
3.3.3.1. Emerging biosimilars market
3.3.3.2. Highly potent active pharmaceutical ingredients
3.3.3.3. Emerging markets
3.3.3.4. Emerging technologies
3.3.4. Global Active Pharmaceutical Ingredients Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Active Pharmaceutical Ingredients Market Analysis and Forecast, 2021-2031 by API (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Branded/ Innovative
4.1.2. Generic
5. Global Active Pharmaceutical Ingredients Market Analysis and Forecast 2021-2031, by Type of Synthesis (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Synthetic
5.1.2. Biotech
6. Global Active Pharmaceutical Ingredients Market Analysis and Forecast, 2021-2031 by Application (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Diabetes
6.1.2. Oncology
6.1.3. Cardiovascular
6.1.4. CNS
6.1.5. Analgesics
6.1.6. Others
7. North America Active Pharmaceutical Ingredients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Active Pharmaceutical Ingredients Market Size and Forecast by API
7.3. North America Active Pharmaceutical Ingredients Market Size and Forecast by Type of Synthesis
7.4. North America Active Pharmaceutical Ingredients Market Size and Forecast by Application
7.5. U.S. Active Pharmaceutical Ingredients Market
7.6. Canada Active Pharmaceutical Ingredients Market
8. Europe Active Pharmaceutical Ingredients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Active Pharmaceutical Ingredients Market Size and Forecast by API
8.3. Europe Active Pharmaceutical Ingredients Market Size and Forecast by Type of Synthesis
8.4. Europe Active Pharmaceutical Ingredients Market Size and Forecast by Application
8.5. UK Active Pharmaceutical Ingredients Market
8.6. Germany Active Pharmaceutical Ingredients Market
8.7. France Active Pharmaceutical Ingredients Market
8.8. Rest of Europe Active Pharmaceutical Ingredients Market
9. Asia Pacific Active Pharmaceutical Ingredients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Active Pharmaceutical Ingredients Market Size and Forecast by API
9.3. Asia Pacific Active Pharmaceutical Ingredients Market Size and Forecast by Type of Synthesis
9.4. Asia Pacific Active Pharmaceutical Ingredients Market Size and Forecast by Application
9.5. China Active Pharmaceutical Ingredients Market
9.6. India Active Pharmaceutical Ingredients Market
9.7. Japan Active Pharmaceutical Ingredients Market
9.8. Rest of Asia Pacific Active Pharmaceutical Ingredients Market
10. Latin America Active Pharmaceutical Ingredients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Active Pharmaceutical Ingredients Market Size and Forecast by API
10.3. Latin America Active Pharmaceutical Ingredients Market Size and Forecast by Type of Synthesis
10.4. Latin America Active Pharmaceutical Ingredients Market Size and Forecast by Application
10.4.1. Brazil Active Pharmaceutical Ingredients Market
10.4.2. Mexico Active Pharmaceutical Ingredients Market
10.4.3. Rest of Latin America Active Pharmaceutical Ingredients Market
11. MEA Active Pharmaceutical Ingredients Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Active Pharmaceutical Ingredients Market Size and Forecast by API
11.3. MEA Active Pharmaceutical Ingredients Market Size and Forecast by Type of Synthesis
11.4. MEA Active Pharmaceutical Ingredients Market Size and Forecast by Application
11.5. GCC Active Pharmaceutical Ingredients Market
11.6. South Africa Active Pharmaceutical Ingredients Market
11.7. Rest of MEA Active Pharmaceutical Ingredients Market
12. Companies in the Active Pharmaceutical Ingredients Market
12.1. AbbVie Inc.
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Sun Pharmaceutical Industries Ltd.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. Cipla Inc.
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Teva Pharmaceutical Industries Ltd.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. Mylan N.V.
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Boehringer Ingelheim International GmbH
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Merck & Co.
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. Bristol-Myers Squibb Company
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. Albemarle Corporation
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. Dr. Reddy’s Laboratories Ltd.
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form

LIST OF TABLES
Table 1 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Active Pharmaceutical Ingredients Market Drivers & Restraints 2020
Table 7 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 18 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 19 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 20 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 37 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 38 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 39 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 40 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 41 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 42 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 43 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 44 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 45 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 46 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 47 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 48 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 49 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 57 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 58 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 59 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 60 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 50 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 51 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 52 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 53 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 54 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 55 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 61 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 62 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 63 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 64 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 65 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 66 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 67 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 68 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 69 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 70 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 71 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 72 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 73 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 74 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 75 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 71 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 72 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 73 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 74 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 75 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 71 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 72 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 73 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 74 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 75 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 76 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 77 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 78 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 79 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 80 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 81 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 172 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 173 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 174 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 175 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 176 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 177 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 178 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 179 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 180 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 181 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 182 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 183 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 184 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 185 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 186 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 187 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 188 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 189 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 190 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 191 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 192 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 193 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 194 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 195 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 196 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 197 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 198 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 199 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 200 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 201 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 202 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 203 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 204 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 205 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 206 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 207 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 208 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 209 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 210 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 211 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 212 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 213 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 214 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 215 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 216 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 217 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 218 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 219 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 220 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 221 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 222 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 223 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 224 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 225 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 226 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 227 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 228 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 229 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 230 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 231 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 232 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236 Leading 10 Active Pharmaceutical Ingredients Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 237 Allergy therapeutics Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 238 Allergy therapeutics Active Pharmaceutical Ingredients Selected Recent Contracts 2019 (Date, Contract API, Details)
Table 239 Allergy therapeutics Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 240 Sun Pharmaceutical Industries Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 241 Sun Pharmaceutical Industries Ltd. Active Pharmaceutical Ingredients Selected Recent Contracts 2019 (Date, Contract API, Details)
Table 242 Sun Pharmaceutical Industries Ltd. Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 243 Cipla Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 244 Cipla Inc. Active Pharmaceutical Ingredients Selected Recent Contracts 2017-2019 (Date, Contract API, Details)
Table 245 Cipla Inc. Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 246 Teva Pharmaceutical Industries Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 247 Teva Pharmaceutical Industries Ltd. Active Pharmaceutical Ingredients Selected Recent Contracts 2015-2019 (Date, Contract API, Details)
Table 248 Teva Pharmaceutical Industries Ltd. Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 249 Mylan N.V. Profile 2019 (CEO, HQ, Founded, Website)
Table 250 Mylan N.V. Active Pharmaceutical Ingredients Selected Recent Contracts 2015-2019 (Date, Contract API, Details)
Table 251 Mylan N.V. Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 252 Boehringer Ingelheim International GmbH Profile 2019 (CEO, HQ, Founded, Website)
Table 253 Boehringer Ingelheim International GmbH Active Pharmaceutical Ingredients Selected Recent Contracts 2015-2019 (Date, Contract API, Details)
Table 254 Boehringer Ingelheim International GmbH Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 255 Merck & Co. Profile 2019 (CEO, HQ, Founded, Website)
Table 256 Merck & Co. Active Pharmaceutical Ingredients Selected Recent Contracts 2015-2019 (Date, Contract API, Details)
Table 257 Merck & Co. Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 258 Bristol-Myers Squibb Company Profile 2019 (CEO, HQ, Founded, Website)
Table 259 Bristol-Myers Squibb Company Active Pharmaceutical Ingredients Selected Recent Contracts 2015-2019 (Date, Contract API, Details)
Table 260 Bristol-Myers Squibb Company Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 261 Albemarle Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 262 Albemarle Corporation Active Pharmaceutical Ingredients Selected Recent Contracts 2015-2019 (Date, Contract API, Details)
Table 263 Albemarle Corporation Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 264 Dr. Reddy’s Laboratories Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 265 Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients Selected Recent Contracts 2015-2019 (Date, Contract API, Details)
Table 266 Dr. Reddy’s Laboratories Ltd. Active Pharmaceutical Ingredients Product Offering (Segment, Product Offerings)
Table 267 Other Companies Involved in the Active Pharmaceutical Ingredients Market 2020 (Company, Location)

LIST OF FIGURES
Figure 1 Allergy Immunotherapy Market by API Overview
Figure 2 Allergy Immunotherapy Market by Type of Synthesis Overview
Figure 3 Allergy Immunotherapy Market by Application Overview
Figure 4 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 5 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 6 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 7 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 8 Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 9 Active Pharmaceutical Ingredients Market Drivers & Restraints 2020
Figure 10 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 11 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 12 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 13 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 14 Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 15 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 16 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 17 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 18 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 19 Branded/ Innovative Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 20 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 21 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 22 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 23 Generic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 24 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 25 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 26 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 27 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 28 Active Pharmaceutical Ingredients Submarket Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 29 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 30 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 31 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 32 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 33 Synthetic Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 34 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 35 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 36 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 37 Biotech Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 38 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 39 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 40 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 41 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 42 Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 43 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 44 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 45 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 46 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 47 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 48 Diabetes Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 49 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 50 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 51 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 52 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 53 Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 54 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 55 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 56 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 57 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 58 Cardiovascular Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 59 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 60 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 61 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 62 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 63 CNS Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 64 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 65 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 66 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 67 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 68 Analgesics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 69 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 70 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 71 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 72 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 73 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 74 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 75 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 76 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 77 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 78 Regional Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 79 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 80 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 81 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 82 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 83 North America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 84 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 85 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 86 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 87 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 88 North America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 89 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 90 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 91 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 92 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 93 North America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 94 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 95 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 96 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 97 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 98 North America Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 99 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 100 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 101 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 102 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 103 US Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 104 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 105 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 106 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 107 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 108 Canada Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 109 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 110 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 111 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 112 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 113 Europe Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 114 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 115 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 116 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 117 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 118 Europe Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 119 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 120 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 121 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 122 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 123 Europe Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 124 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 125 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 126 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 127 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 128 Europe Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 129 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 130 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 131 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 132 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 133 UK Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 134 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 135 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 136 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 137 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 138 Germany Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 139 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 140 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 141 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 142 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 143 France Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 144 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 145 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 146 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 147 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 148 Rest of Europe Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 149 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 150 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 151 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 152 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 153 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 154 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 155 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 156 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 157 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 158 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 159 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 160 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 161 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 162 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 163 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 164 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 165 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 166 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 167 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 168 Asia Pacific Active Pharmaceutical Ingredients Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 169 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 170 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 171 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 172 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 173 China Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 174 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 175 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 176 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 177 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 178 India Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 179 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 180 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 181 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 182 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 183 Japan Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 184 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 185 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 186 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 187 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 188 RoAPAC Active Pharmaceutical Ingredients Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 189 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 190 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 191 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 192 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 193 Middle East Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 194 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 195 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 196 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 197 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 198 Middle East Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 199 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 200 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 201 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 202 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 203 Middle East Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 204 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 205 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 206 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 207 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 208 Latin America Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 209 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 210 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 211 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 212 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 213 Latin America Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 214 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 215 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 216 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 217 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 218 Latin America Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 219 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 220 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 221 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 222 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 223 Africa Active Pharmaceutical Ingredients Market Forecast by API 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 224 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 225 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 226 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 227 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 228 Africa Active Pharmaceutical Ingredients Market Forecast by Type of Synthesis 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 229 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 230 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 231 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 232 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 233 Africa Active Pharmaceutical Ingredients Market Forecast by Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)

Companies Profiled in the Report
1. AbbVie Inc.
2. Teva Pharmaceutical Industries Ltd.
3. Mylan N.V.
4. Cipla Inc.
5. Boehringer Ingelheim International GmbH
6. Merck & Co., Inc.
7. Sun Pharmaceutical Industries Ltd.
8. Bristol-Myers Squibb Company
9. Albemarle Corporation
10. Aurobindo Pharma
11. Dr. Reddy’s Laboratories Ltd.

List of Companies Mentioned in the Report:
1. Shionogi & Co.
2. Shanghai Fosun Pharmaceutical
3. Stada Arzneimittel
4. Lundbeck
5. Zhejiang International
6. Lupin
7. Taisho Pharmaceutical
8. Tasly Pharmaceutical
9. Ipsen
10. Sino Biopharmaceutical
11. Ono Pharmaceutical
12. Aurobindo
13. Cipla
14. Johnson & Johnson
15. Roche
16. Novartis
17. Sanofi
18. Bayer
19. Merck & Co. (MSD)
20. Eli Lilly
21. Astrazeneca
22. Teva
23. CR Pharmaceutical
24. Bristol-Myers Squibb
25. Merck (KGaA)
26. Novo Nordisk
27. Takeda
28. Allergan
29. Astellas Pharma
30. Mylan
31. Otsuka
32. Daiichi Sankyo
33. Valeant Pharmaceuticals
34. UCB
35. Zoetis
36. Eisai
37. Chugai Pharmaceutical
38. Perrigo
39. Sun Pharmaceutical
40. Mitsubishi Tanabe Pharma
41. Sichuan Languang Development
42. Sumitomo Dainippon Pharma
43. Yunnan Baiyao
44. Aspen Pharmacare
45. Endo
46. Kangmei Pharmaceutical
47. Galenica
48. Guangzhou Baiyunshan Pharmaceutical
49. Kyowa Hakko Kirin
50. Mallinckrod

List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care

Download sample pages

Complete the form below to download your free sample pages for Active Pharmaceutical Ingredients Market Report to 2031

Download sample pages

Complete the form below to download your free sample pages for Active Pharmaceutical Ingredients Market Report to 2031

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033

The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.

03 October 2023

READ

Visiongain Publishes Bioreactors Market Report 2023-2033

The global Bioreactors market was estimated to be valued at US$9,977.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.

29 September 2023

READ

Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.

27 September 2023

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.

25 September 2023

READ

Industries > Pharma > Active Pharmaceutical Ingredients Market Report to 2031

Back to Pharma Reports

Active Pharmaceutical Ingredients Market Report to 2031

Forecasts by API (Branded/ Innovative and Generic), by Type of Synthesis (Synthetic and Biotech), by Application (Diabetes, Oncology, Cardiovascular, CNS, Analgesics, and Others) PLUS COVID-19 Recovery Scenarios

Download sample pages

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033

Visiongain Publishes Bioreactors Market Report 2023-2033

Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

Our Clients